MRD-Guided Venetoclax Plus Obinutuzumab Therapy for CLL
Data suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable MRD may be able to discontinue therapy early.
Data suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable MRD may be able to discontinue therapy early.
Targeted oral treatment options for CLL and SLL are medications taken by mouth that identify and attack specific cancer cells.
A variety of tests are used to capture images inside the body when chronic lymphocytic leukemia (CLL) and small
lymphocytic lymphoma (SLL) are present. Imaging tests are used to look inside the body to capture pictures that will help the healthcare team visualize what, if any, internal changes might be occurring.
A clinical trial for those living with CLL and SLL is a carefully controlled research study to improve the overall care and treatment.
Clinician Resource Library: Informational Handouts Click below on each of the topical handouts to view and print copies on demand. You may also order a free Welcome Kit which includes a
Staging in cancer is a process used to determine the extent to which cancer has spread in the body, predict its progression, and guide treatment decisions.
Many individuals diagnosed with CLL and SLL face a variety of stressors after being diagnosed, one of which is often the financial strain.
Chimeric Antigen Receptor T-cell (CAR-T) therapy is a potent cellular immune treatment that genetically trains an individual’s immune system (specifically, the T-cells, a type of white blood cell) to both recognize and attack cancerous cells.
Most people who have been diagnosed with CLL or SLL have no symptoms initially and are usually advised that no treatment is necessary upon diagnosis
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |